---
document_datetime: 2025-12-02 05:37:56
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/fabrazyme.html
document_name: fabrazyme.html
version: success
processing_time: 0.1154245
conversion_datetime: 2025-12-28 00:49:50.045123
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Fabrazyme

[RSS](/en/individual-human-medicine.xml/65458)

##### Authorised

This medicine is authorised for use in the European Union

agalsidase beta Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Fabrazyme](#news-on)
- [More information on Fabrazyme](#more-information-on-fabrazyme-443)
- [More information on Fabrazyme](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR). It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach its recommendations on how to use the medicine.

If you need more information about your medical condition or your treatment, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. If you want more information on the basis of the CHMP recommendations, read the scientific discussion (also part of the EPAR).

Expand section

Collapse section

## What is Fabrazyme?

Fabrazyme is a solution for infusion (drip into a vein) containing the active substance agalsidase beta.

## What is Fabrazyme used for?

Fabrazyme is used to treat patients who have Fabry disease, a rare inherited disorder. Patients with Fabry disease do not have enough of an enzyme called alpha-galactosidase A. This enzyme normally breaks down a fatty substance called globotriaosylceramide (GL-3). If the enzyme is not present, GL-3 cannot be broken down and it builds up in the body's cells, such as kidney cells.

People with Fabry disease may have a wide range of signs and symptoms, including severe conditions such as kidney failure, heart problems and stroke.

Because the number of patients with Fabry disease is low, the disease is considered 'rare', and Fabrazyme was designated an 'orphan medicine' (a medicine used in rare diseases) on 8 August 2000.

The medicine can only be obtained with a prescription.

## How is Fabrazyme used?

Only a doctor who has experience in treating patients with Fabry disease or other inherited metabolic diseases should give Fabrazyme. It is used as an intravenous infusion of 1 mg per kilogram body weight given once every two weeks. The starting infusion rate should be no more than 0.25 mg per minute (15 mg per hour) to reduce the risk of infusion-related side effects. The infusion rate may be increased gradually with further infusions. One study has looked at what happens to Fabrazyme when given to children and suggested that Fabrazyme could be used in children between eight and 16 years of age at the same dose. Patients who have severe kidney damage may have a weaker response to treatment. Fabrazyme is intended for long-term use.

## How does Fabrazyme work?

Fabrazyme is an enzyme replacement therapy. Enzyme replacement therapies provide patients with the enzyme they are lacking. Fabrazyme is designed to replace the human enzyme alpha-galactosidase A, which people with Fabry disease are lacking. The active substance in Fabrazyme, agalsidase beta, is a copy of the human enzyme, produced by a method known as 'recombinant DNA technology': it is made by a cell that has received a gene (DNA), which makes it able to produce the enzyme. The replacement enzyme helps to break down GL-3 and stops it building up (accumulating) in the patient's cells.

## How has Fabrazyme been studied?

Three clinical studies involving a total of 73 adult patients were presented. In the main study, Fabrazyme was compared with placebo (a dummy treatment) in 58 patients. The study looked at the effect of the medicines on clearing GL-3 from the kidney.

The effectiveness of Fabrazyme was also tested in 16 children aged between eight and 16 years who had Fabry disease.

## What benefit has Fabrazyme shown during the studies?

In the main study, Fabrazyme produced a highly significant and almost complete clearance of GL-3 in the kidney cells after 20 weeks of treatment: 69% of the patients treated with Fabrazyme had the best score for clearance, compared with none of the patients in the placebo group. This might lead to the symptoms of the disease improving or the disease becoming stable.

Children treated with Fabrazyme also had decreases in levels of GL-3 in the blood, with all children having normal levels after 20 weeks of treatment. This was accompanied by improvements in the children's symptoms and quality of life.

## What is the risk associated with Fabrazyme?

The most common side effects with Fabrazyme (seen in more than 1 patient in 10) are caused by the infusion rather than the medicine. These reactions are mainly fever and chills. Other very common side effects include headache, paraesthesia (abnormal sensations like pins and needles), nausea (feeling sick), vomiting, flushing and feeling cold. Side effects reported in children are similar to those seen in adult patients. For the full list of all side effects reported with Fabrazyme, see the package leaflet.

Patients who receive Fabrazyme can develop antibodies (proteins that are produced in response to Fabrazyme and can affect treatment).

Fabrazyme should not be used in people who may be hypersensitive (allergic) to agalsidase beta or any of the other ingredients.

## Why has Fabrazyme been approved?

The Committee for Medicinal Products for Human Use (CHMP) decided that, for patients with Fabry disease, treatment with Fabrazyme might provide long-term clinical benefits. The CHMP decided that Fabrazyme's benefits are greater than its risks for long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease. The Committee recommended that Fabrazyme be given marketing authorisation.

Fabrazyme was originally authorised under 'exceptional circumstances', because, as the disease is rare, limited information was available at the time of approval. As the company had supplied the additional information requested, the 'exceptional circumstances' ended on 6 February 2008.

## Other information about Fabrazyme

The European Commission granted a marketing authorisation valid throughout the European Union for Fabrazyme to Genzyme Europe B.V. on 3 August 2001. The marketing authorisation was renewed on 3 August 2006.

Fabrazyme : EPAR - Summary for the public

English (EN) (75.52 KB - PDF)

**First published:** 10/04/2008

**Last updated:** 19/03/2013

[View](/en/documents/overview/fabrazyme-epar-summary-public_en.pdf)

[Other languages (21)](#file-language-dropdown-635)

български (BG) (127.41 KB - PDF)

**First published:**

10/04/2008

**Last updated:**

19/03/2013

[View](/bg/documents/overview/fabrazyme-epar-summary-public_bg.pdf)

español (ES) (97.03 KB - PDF)

**First published:**

10/04/2008

**Last updated:**

19/03/2013

[View](/es/documents/overview/fabrazyme-epar-summary-public_es.pdf)

čeština (CS) (123.85 KB - PDF)

**First published:**

10/04/2008

**Last updated:**

19/03/2013

[View](/cs/documents/overview/fabrazyme-epar-summary-public_cs.pdf)

dansk (DA) (96.76 KB - PDF)

**First published:**

10/04/2008

**Last updated:**

19/03/2013

[View](/da/documents/overview/fabrazyme-epar-summary-public_da.pdf)

Deutsch (DE) (98.23 KB - PDF)

**First published:**

10/04/2008

**Last updated:**

19/03/2013

[View](/de/documents/overview/fabrazyme-epar-summary-public_de.pdf)

eesti keel (ET) (75.93 KB - PDF)

**First published:**

10/04/2008

**Last updated:**

19/03/2013

[View](/et/documents/overview/fabrazyme-epar-summary-public_et.pdf)

ελληνικά (EL) (126.92 KB - PDF)

**First published:**

10/04/2008

**Last updated:**

19/03/2013

[View](/el/documents/overview/fabrazyme-epar-summary-public_el.pdf)

français (FR) (100.19 KB - PDF)

**First published:**

10/04/2008

**Last updated:**

19/03/2013

[View](/fr/documents/overview/fabrazyme-epar-summary-public_fr.pdf)

italiano (IT) (99.73 KB - PDF)

**First published:**

10/04/2008

**Last updated:**

19/03/2013

[View](/it/documents/overview/fabrazyme-epar-summary-public_it.pdf)

latviešu valoda (LV) (97.31 KB - PDF)

**First published:**

10/04/2008

**Last updated:**

19/03/2013

[View](/lv/documents/overview/fabrazyme-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (121.36 KB - PDF)

**First published:**

10/04/2008

**Last updated:**

19/03/2013

[View](/lt/documents/overview/fabrazyme-epar-summary-public_lt.pdf)

magyar (HU) (117.42 KB - PDF)

**First published:**

10/04/2008

**Last updated:**

19/03/2013

[View](/hu/documents/overview/fabrazyme-epar-summary-public_hu.pdf)

Malti (MT) (102.47 KB - PDF)

**First published:**

10/04/2008

**Last updated:**

19/03/2013

[View](/mt/documents/overview/fabrazyme-epar-summary-public_mt.pdf)

Nederlands (NL) (111 KB - PDF)

**First published:**

10/04/2008

**Last updated:**

19/03/2013

[View](/nl/documents/overview/fabrazyme-epar-summary-public_nl.pdf)

polski (PL) (122.76 KB - PDF)

**First published:**

10/04/2008

**Last updated:**

19/03/2013

[View](/pl/documents/overview/fabrazyme-epar-summary-public_pl.pdf)

português (PT) (75.08 KB - PDF)

**First published:**

10/04/2008

**Last updated:**

19/03/2013

[View](/pt/documents/overview/fabrazyme-epar-summary-public_pt.pdf)

română (RO) (121.35 KB - PDF)

**First published:**

10/04/2008

**Last updated:**

19/03/2013

[View](/ro/documents/overview/fabrazyme-epar-summary-public_ro.pdf)

slovenčina (SK) (124.69 KB - PDF)

**First published:**

10/04/2008

**Last updated:**

19/03/2013

[View](/sk/documents/overview/fabrazyme-epar-summary-public_sk.pdf)

slovenščina (SL) (114.37 KB - PDF)

**First published:**

10/04/2008

**Last updated:**

19/03/2013

[View](/sl/documents/overview/fabrazyme-epar-summary-public_sl.pdf)

Suomi (FI) (103.55 KB - PDF)

**First published:**

10/04/2008

**Last updated:**

19/03/2013

[View](/fi/documents/overview/fabrazyme-epar-summary-public_fi.pdf)

svenska (SV) (96.84 KB - PDF)

**First published:**

10/04/2008

**Last updated:**

19/03/2013

[View](/sv/documents/overview/fabrazyme-epar-summary-public_sv.pdf)

Fabrazyme : EPAR - Risk-management-plan summary

English (EN) (151.18 KB - PDF)

**First published:** 29/05/2020

[View](/en/documents/rmp-summary/fabrazyme-epar-risk-management-plan-summary_en.pdf)

## Product information

Fabrazyme : EPAR - Product Information

English (EN) (321 KB - PDF)

**First published:** 20/07/2009

**Last updated:** 04/09/2024

[View](/en/documents/product-information/fabrazyme-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-210)

български (BG) (677.05 KB - PDF)

**First published:**

20/07/2009

**Last updated:**

04/09/2024

[View](/bg/documents/product-information/fabrazyme-epar-product-information_bg.pdf)

español (ES) (451.14 KB - PDF)

**First published:**

20/07/2009

**Last updated:**

04/09/2024

[View](/es/documents/product-information/fabrazyme-epar-product-information_es.pdf)

čeština (CS) (703.59 KB - PDF)

**First published:**

20/07/2009

**Last updated:**

04/09/2024

[View](/cs/documents/product-information/fabrazyme-epar-product-information_cs.pdf)

dansk (DA) (433.77 KB - PDF)

**First published:**

20/07/2009

**Last updated:**

04/09/2024

[View](/da/documents/product-information/fabrazyme-epar-product-information_da.pdf)

Deutsch (DE) (836.02 KB - PDF)

**First published:**

20/07/2009

**Last updated:**

04/09/2024

[View](/de/documents/product-information/fabrazyme-epar-product-information_de.pdf)

eesti keel (ET) (629.12 KB - PDF)

**First published:**

20/07/2009

**Last updated:**

04/09/2024

[View](/et/documents/product-information/fabrazyme-epar-product-information_et.pdf)

ελληνικά (EL) (537.31 KB - PDF)

**First published:**

20/07/2009

**Last updated:**

04/09/2024

[View](/el/documents/product-information/fabrazyme-epar-product-information_el.pdf)

français (FR) (587.2 KB - PDF)

**First published:**

20/07/2009

**Last updated:**

04/09/2024

[View](/fr/documents/product-information/fabrazyme-epar-product-information_fr.pdf)

hrvatski (HR) (592.31 KB - PDF)

**First published:**

20/07/2009

**Last updated:**

04/09/2024

[View](/hr/documents/product-information/fabrazyme-epar-product-information_hr.pdf)

íslenska (IS) (737.19 KB - PDF)

**First published:**

20/07/2009

**Last updated:**

04/09/2024

[View](/is/documents/product-information/fabrazyme-epar-product-information_is.pdf)

italiano (IT) (703.87 KB - PDF)

**First published:**

20/07/2009

**Last updated:**

04/09/2024

[View](/it/documents/product-information/fabrazyme-epar-product-information_it.pdf)

latviešu valoda (LV) (754.15 KB - PDF)

**First published:**

20/07/2009

**Last updated:**

04/09/2024

[View](/lv/documents/product-information/fabrazyme-epar-product-information_lv.pdf)

lietuvių kalba (LT) (641.38 KB - PDF)

**First published:**

20/07/2009

**Last updated:**

04/09/2024

[View](/lt/documents/product-information/fabrazyme-epar-product-information_lt.pdf)

magyar (HU) (786.98 KB - PDF)

**First published:**

20/07/2009

**Last updated:**

04/09/2024

[View](/hu/documents/product-information/fabrazyme-epar-product-information_hu.pdf)

Malti (MT) (666.07 KB - PDF)

**First published:**

20/07/2009

**Last updated:**

04/09/2024

[View](/mt/documents/product-information/fabrazyme-epar-product-information_mt.pdf)

Nederlands (NL) (646.62 KB - PDF)

**First published:**

20/07/2009

**Last updated:**

04/09/2024

[View](/nl/documents/product-information/fabrazyme-epar-product-information_nl.pdf)

norsk (NO) (459.42 KB - PDF)

**First published:**

20/07/2009

**Last updated:**

04/09/2024

[View](/no/documents/product-information/fabrazyme-epar-product-information_no.pdf)

polski (PL) (548.4 KB - PDF)

**First published:**

20/07/2009

**Last updated:**

04/09/2024

[View](/pl/documents/product-information/fabrazyme-epar-product-information_pl.pdf)

português (PT) (455.68 KB - PDF)

**First published:**

20/07/2009

**Last updated:**

04/09/2024

[View](/pt/documents/product-information/fabrazyme-epar-product-information_pt.pdf)

română (RO) (657.37 KB - PDF)

**First published:**

20/07/2009

**Last updated:**

04/09/2024

[View](/ro/documents/product-information/fabrazyme-epar-product-information_ro.pdf)

slovenčina (SK) (708.58 KB - PDF)

**First published:**

20/07/2009

**Last updated:**

04/09/2024

[View](/sk/documents/product-information/fabrazyme-epar-product-information_sk.pdf)

slovenščina (SL) (715.35 KB - PDF)

**First published:**

20/07/2009

**Last updated:**

04/09/2024

[View](/sl/documents/product-information/fabrazyme-epar-product-information_sl.pdf)

Suomi (FI) (635.71 KB - PDF)

**First published:**

20/07/2009

**Last updated:**

04/09/2024

[View](/fi/documents/product-information/fabrazyme-epar-product-information_fi.pdf)

svenska (SV) (732.69 KB - PDF)

**First published:**

20/07/2009

**Last updated:**

04/09/2024

[View](/sv/documents/product-information/fabrazyme-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** N/0130 30/07/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Fabrazyme : EPAR - All Authorised presentations

English (EN) (60.74 KB - PDF)

**First published:** 21/12/2005

**Last updated:** 15/07/2021

[View](/en/documents/all-authorised-presentations/fabrazyme-epar-all-authorised-presentations_en.pdf)

[Other languages (22)](#file-language-dropdown-716)

български (BG) (49.82 KB - PDF)

**First published:**

21/12/2005

**Last updated:**

15/07/2021

[View](/bg/documents/all-authorised-presentations/fabrazyme-epar-all-authorised-presentations_bg.pdf)

español (ES) (59.76 KB - PDF)

**First published:**

21/12/2005

**Last updated:**

15/07/2021

[View](/es/documents/all-authorised-presentations/fabrazyme-epar-all-authorised-presentations_es.pdf)

čeština (CS) (98.29 KB - PDF)

**First published:**

21/12/2005

**Last updated:**

15/07/2021

[View](/cs/documents/all-authorised-presentations/fabrazyme-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (62.93 KB - PDF)

**First published:**

21/12/2005

**Last updated:**

15/07/2021

[View](/da/documents/all-authorised-presentations/fabrazyme-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (65.12 KB - PDF)

**First published:**

21/12/2005

**Last updated:**

15/07/2021

[View](/de/documents/all-authorised-presentations/fabrazyme-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (10.74 KB - PDF)

**First published:**

21/12/2005

**Last updated:**

15/07/2021

[View](/et/documents/all-authorised-presentations/fabrazyme-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (81.36 KB - PDF)

**First published:**

21/12/2005

**Last updated:**

15/07/2021

[View](/el/documents/all-authorised-presentations/fabrazyme-epar-all-authorised-presentations_el.pdf)

français (FR) (59.82 KB - PDF)

**First published:**

21/12/2005

**Last updated:**

15/07/2021

[View](/fr/documents/all-authorised-presentations/fabrazyme-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (53.52 KB - PDF)

**First published:**

21/12/2005

**Last updated:**

15/07/2021

[View](/hr/documents/all-authorised-presentations/fabrazyme-epar-all-authorised-presentations_hr.pdf)

italiano (IT) (57.82 KB - PDF)

**First published:**

21/12/2005

**Last updated:**

15/07/2021

[View](/it/documents/all-authorised-presentations/fabrazyme-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (99.05 KB - PDF)

**First published:**

21/12/2005

**Last updated:**

15/07/2021

[View](/lv/documents/all-authorised-presentations/fabrazyme-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (94.55 KB - PDF)

**First published:**

21/12/2005

**Last updated:**

15/07/2021

[View](/lt/documents/all-authorised-presentations/fabrazyme-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (49.2 KB - PDF)

**First published:**

21/12/2005

**Last updated:**

15/07/2021

[View](/hu/documents/all-authorised-presentations/fabrazyme-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (63.72 KB - PDF)

**First published:**

21/12/2005

**Last updated:**

15/07/2021

[View](/mt/documents/all-authorised-presentations/fabrazyme-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (60.32 KB - PDF)

**First published:**

21/12/2005

**Last updated:**

15/07/2021

[View](/nl/documents/all-authorised-presentations/fabrazyme-epar-all-authorised-presentations_nl.pdf)

polski (PL) (96.46 KB - PDF)

**First published:**

21/12/2005

**Last updated:**

15/07/2021

[View](/pl/documents/all-authorised-presentations/fabrazyme-epar-all-authorised-presentations_pl.pdf)

português (PT) (60.11 KB - PDF)

**First published:**

21/12/2005

**Last updated:**

15/07/2021

[View](/pt/documents/all-authorised-presentations/fabrazyme-epar-all-authorised-presentations_pt.pdf)

română (RO) (35.85 KB - PDF)

**First published:**

21/12/2005

**Last updated:**

15/07/2021

[View](/ro/documents/all-authorised-presentations/fabrazyme-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (49.63 KB - PDF)

**First published:**

21/12/2005

**Last updated:**

15/07/2021

[View](/sk/documents/all-authorised-presentations/fabrazyme-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (10.51 KB - PDF)

**First published:**

21/12/2005

**Last updated:**

15/07/2021

[View](/sl/documents/all-authorised-presentations/fabrazyme-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (58.64 KB - PDF)

**First published:**

21/12/2005

**Last updated:**

15/07/2021

[View](/fi/documents/all-authorised-presentations/fabrazyme-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (60.62 KB - PDF)

**First published:**

21/12/2005

**Last updated:**

15/07/2021

[View](/sv/documents/all-authorised-presentations/fabrazyme-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Fabrazyme Active substance agalsidase beta International non-proprietary name (INN) or common name agalsidase beta Therapeutic area (MeSH) Fabry Disease Anatomical therapeutic chemical (ATC) code A16AB04

### Pharmacotherapeutic group

Other alimentary tract and metabolism products

### Therapeutic indication

Fabrazyme is indicated for long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease (?-galactosidase-A deficiency).

## Authorisation details

EMA product number EMEA/H/C/000370 Marketing authorisation holder

Sanofi B.V.

Paasheuvelweg 25

Opinion adopted 29/03/2001 Marketing authorisation issued 03/08/2001 Revision 37

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Fabrazyme : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (261.11 KB - PDF)

**First published:** 20/07/2009

**Last updated:** 04/09/2024

[View](/en/documents/procedural-steps-after/fabrazyme-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Fabrazyme-H-C-370-P46-0064 : EPAR - Assessment Report

Reference Number: EMA/587427/2023

English (EN) (433.54 KB - PDF)

**First published:** 13/02/2024

[View](/en/documents/variation-report/fabrazyme-h-c-370-p46-0064-epar-assessment-report_en.pdf)

Fabrazyme-H-C-P46-063 : EPAR - Assessment Report

Adopted

Reference Number: EMA/502070/2016

English (EN) (678.3 KB - PDF)

**First published:** 20/07/2016

**Last updated:** 20/07/2016

[View](/en/documents/variation-report/fabrazyme-h-c-p46-063-epar-assessment-report_en.pdf)

Fabrazyme-H-C-370-P46-0062 : EPAR - Assessment Report

Adopted

Reference Number: EMA/56436/2015

English (EN) (101.81 KB - PDF)

**First published:** 05/02/2015

**Last updated:** 05/02/2015

[View](/en/documents/variation-report/fabrazyme-h-c-370-p46-0062-epar-assessment-report_en.pdf)

Fabrazyme : EPAR - Steps taken after authorisation when a cutoff date has been used

English (EN) (85.3 KB - PDF)

**First published:** 21/12/2005

**Last updated:** 21/12/2005

[View](/en/documents/steps-after-cutoff/fabrazyme-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf)

## Initial marketing authorisation documents

Fabrazyme : EPAR - Scientific discussion

English (EN) (248.26 KB - PDF)

**First published:** 21/12/2005

**Last updated:** 21/12/2005

[View](/en/documents/scientific-discussion/fabrazyme-epar-scientific-discussion_en.pdf)

Fabrazyme : EPAR - Procedural steps taken before authorisation

English (EN) (94.54 KB - PDF)

**First published:** 21/12/2005

**Last updated:** 21/12/2005

[View](/en/documents/procedural-steps/fabrazyme-epar-procedural-steps-taken-authorisation_en.pdf)

#### News on Fabrazyme

[European Medicines Agency reviews treatment recommendations for Fabrazyme](/en/news/european-medicines-agency-reviews-treatment-recommendations-fabrazyme) 22/10/2010

[European Medicines Agency updates treatment recommendations because of continued Fabrazyme shortage](/en/news/european-medicines-agency-updates-treatment-recommendations-because-continued-fabrazyme-shortage) 06/07/2010

[European Medicines Agency gives new temporary treatment recommendations for Fabrazyme](/en/news/european-medicines-agency-gives-new-temporary-treatment-recommendations-fabrazyme) 23/04/2010

[Supply shortage of Fabrazyme - updated treatment recommendations required for adult male patients](/en/news/supply-shortage-fabrazyme-updated-treatment-recommendations-required-adult-male-patients) 25/09/2009

[Supply shortages of Cerezyme and Fabrazyme - priority access for patients most in need of treatment recommended](/en/news/supply-shortages-cerezyme-fabrazyme-priority-access-patients-most-need-treatment-recommended) 25/06/2009

#### More information on Fabrazyme

This product is no longer an orphan medicine. It was originally [designated an orphan medicine](/en/medicines/human/orphan-designations/eu300003) on 8 August 2000. Fabrazyme was withdrawn from the Community register of orphan medicinal products in August 2011 at the end of the 10-year period of market exclusivity.

#### More information on Fabrazyme

- [Fabrazyme - supply shortage](/en/medicines/human/shortages/fabrazyme)
- [Fabrazyme (agalsidase beta) home infusion educational materials effectiveness evaluation: a survey for healthcare providers and patients/caregivers (Fabrazyme Home Infusion Ed Mat Survey) - post-authorisation study](https://catalogues.ema.europa.eu/study/35382)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 04/09/2024

## Share this page

[Back to top](#main-content)